Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2003
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024921A1 Alkyl urea retinoid agonists i
03/27/2003WO2003024920A1 Substituted urea retinoid agonists ii
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024489A2 Combination of a nsaid and a pde-4 inhibitor
03/27/2003WO2003024487A1 Method of increasing the presence of glutathione in cells
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024475A1 Water-insoluble sustained release compositions, preparations thereof and process for producing the same
03/27/2003WO2003024455A2 Stent coated with a sustained-release drug delivery and method for use thereof
03/27/2003WO2003024453A1 Excitatory amino acid receptor antagonists
03/27/2003WO2003024452A1 Novel medicaments for inhalation
03/27/2003WO2003024449A1 Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments
03/27/2003WO2003024448A2 Inhibitors of histone deacetylase
03/27/2003WO2003024446A1 Oxidation stress inhibitor and method of measuring oxidation stress
03/27/2003WO2003024444A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
03/27/2003WO2003024442A2 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024436A2 Method for treating skin disorders
03/27/2003WO2003024404A2 Chemokines as adjuvants of immune response
03/27/2003WO2003024402A2 Lpa receptor agonists and antagonists and methods of use
03/27/2003WO2003024392A2 Compositions and methods for the diagnosis and treatment of tumor
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024354A2 Interleukin-12 as a veterinary vaccine adjuvant
03/27/2003WO2003024223A1 Pesticidal formulations
03/27/2003WO2003024183A2 Wortmannin analogs and methods of using same
03/27/2003WO2002100352A3 Nr2b receptor antagonists for the treatment or prevention of migraines
03/27/2003WO2002098854A3 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002091990A3 Prevention of addiction in pain management
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002060879A3 Bacterial gyrase inhibitors and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002053190A3 Particles for inhalation having sustained release properties
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002053089A3 Stable skin conditioning compositions containing retinoid boosters
03/27/2003WO2002040508A3 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
03/27/2003WO2002033086A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/27/2003WO2002030915A3 Aryl-indane compounds for use as inhibitors of p-glycoprotein mediated transport
03/27/2003WO2002029060A3 Hematopoietin receptors hpr1 and hpr2
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002028381A3 Methods of inducing cancer cell death and tumor regression
03/27/2003WO2002026951A3 Oxidoreductases
03/27/2003WO2002026220A3 Taxoid conjugates as antimitotic and antitumor agents
03/27/2003WO2002024892A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding them, and uses thereof
03/27/2003WO2002016585A3 Imidazoline receptor homologs
03/27/2003WO2002013802A3 Method of treating estrogen receptor positive carcinoma
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003WO2001090109A9 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
03/27/2003WO2001062954A3 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060621 Preparation of indolopyrrolocarbazole derivative; obtain chemical intermediates, deblock and recover indolopyrrolocarbazole derivative
03/27/2003US20030060511 Method for treatment of ocular hypertension and glaucoma
03/27/2003US20030060510 Administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration
03/27/2003US20030060507 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders
03/27/2003US20030060498 5-arylsulfonyl indoles useful for treating disease
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060485 (+)-norcisapride
03/27/2003US20030060482 Urease inhibitors
03/27/2003US20030060481 The use of scopolamine salts
03/27/2003US20030060477 Administering to a patient a betablocker and a cholesterol-lowering agent to treat atherosclerosis, hyperpoproteinemia and hypercholesterolemia
03/27/2003US20030060474 A piperazine compound as antithrombotic agent
03/27/2003US20030060473 Piperazine compounds as inhibitors of MMP or TNF
03/27/2003US20030060470 Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparation comprising them
03/27/2003US20030060467 Substituted pyrazolo(1,5-d)(1,2,4)triazine derivatives, possessing a substitued or nonsubstituted cycloalkyl, phenyl or heteroaryl substituent at 7-position, an alkyl at 4-position, substituted alkoxy at 2-position; antianxiolytic
03/27/2003US20030060466 Such as 6-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-2-methyl-5-nitro-3-(2,2,2-trifluoro -ethyl)-3H-pyrimidin-4-one, which are metabotropic glutamate receptor antagonists useful in treating psychological disorders
03/27/2003US20030060464 Therapeutic 1H-pyrido [ 4, 3-b ] indoles
03/27/2003US20030060461 Cyclic diamine compound with condensed-ring groups
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060458 Indoles and indolines having 5-HT activity
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060450 Such as 4-(3-chlorophenyl)-6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl) -methyl)-1-methyl-2(1H)quinoline for treating mammalian tumors via inhibiting farnesyl transferase
03/27/2003US20030060443 Inhibition of apoptosis by the expression of antisense RNA of caspase-3
03/27/2003US20030060433 Reducing the severity of cancer
03/27/2003US20030060429 Stilbene derivatives and taxanes, vinca alkaloids, alkylating agents, antimetabolites, epidophylloptoxins, platinum compounds, and antibiotics; antitumor agents
03/27/2003US20030060423 Using cyclohexyl or pyran methylenesulfamate derivatives to treat psychological disorders
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060400 A modified nucleoside comprising a purine or pyrimidine ring for treating viral infections
03/27/2003US20030059922 Sphingosine1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059890 Protein for use as antiinflammatory, antiproliferative and antipyretic agents
03/27/2003US20030059871 Hematopoietin receptors HPR1 and HPR2
03/27/2003US20030059869 Novel G protein-coupled receptor, GAVE3
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059852 Detecting modulators of integrin activity; obtain sample containing integrin, incubate with test compound, monitor adjustment in integrin activity, adjustment in integrin activity indicates modulator
03/27/2003US20030059767 Zinc finger protein derivatives and methods therefor
03/27/2003US20030059479 A cell activating agent comprising a royal jelly and alpha, alpha- trehalose which acts as a stabilizer and preservative at low temperatures; tonic, health food or health supplement; cosmetics
03/27/2003US20030059430 Use of peptides or small molecules in treatment of disease, in high-throughput screening, in use of metal-binding peptides derived from sequences present in CD74-homology domain of insulin-like growth factor
03/27/2003US20030059424 Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
03/27/2003US20030059421 DNA encoding the baboon and cynomolgus macaque prostoglandin E2 receptor EP4 subtype
03/27/2003US20030059401 Composition and method for causing photodynamic damage to target cells
03/27/2003US20030059369 Amyloid plaque aggregation inhibitors and diagnostic imaging agents
03/27/2003US20030056788 Partial liquid breathing of fluorocarbons
03/27/2003CA2466243A1 Indolizines as kinase protein inhibitors
03/27/2003CA2465978A1 Inhibitors of histone deacetylase
1 ... 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 ... 1564